Japan-based Takeda Pharmaceutical has signed a contract with COUR Pharmaceutical Development to acquire an exclusive global license to develop and commercialise COUR's CNP-101 (TAK-101), an immune modifying nanoparticle that contains gliadin proteins that is being developed for the treatment of celiac disease, it was reported yesterday.
The deal is worth up to USD420m.
According to the contract, COUR Pharmaceutical Development will be eligible to receive the amount from the Japanese company in the form of future payments, and royalties on sales of any commercialised products emerging from the TAK-101 license. The investigational drug has been developed on COUR's antigen-specific immune tolerance platform. It targets the aberrant immune response in celiac disease, a serious autoimmune disease in which the ingestion of gluten results in inflammation and damage in the small intestine.
Takeda plans to launch a dose-ranging trial to further investigate the potential of TAK-101 in patients with celiac disease on a gluten-free diet.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca